sponsored by the company of Australian Imugene, a volunteer with metastasized and resistant to previous treatment attempts, has just been administered a “cancer killer”, or oncolytic for scientists. CF33-hNIS or Vaxinia is an orthopoxvirus, like that of monkeypox, modified in the laboratory to express a human – we then speak of a virus – which makes it possible to follow in cells and increase its anti-cancer properties.
The latter is able to infect and kill cancer cells while sparing healthy ones. When the cancer cell dies, it releases virus particles that stimulate thenotably , which then attack their neighbors. ” Our previous research has shown that oncolytic viruses can stimulate the immune system to kill cancer and make it more to other immunotherapies », .
A new approach to cancer on the test bench
The clinical trial will test the safety and tolerance of CF33-hNIS alone or in combination with a therapeutic antibody,, already authorized to treat several cancers. Secondly, the scientists will analyze the ability of the oncolytic virus to reduce the size of .
The real effectiveness of this treatmentwill only be estimated during the later stages of the clinical trial. The investigators hope to enroll a hundred volunteers, adults and suffering from any across the United States and Australia.